Welcome to our dedicated page for Cue Biopharma SEC filings (Ticker: CUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cue Biopharma, Inc. (CUE) SEC filings page provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Delaware-incorporated, Nasdaq-listed clinical-stage biopharmaceutical company (Commission File Number 001-38327), Cue Biopharma uses SEC reports to communicate financial results, material agreements, leadership changes and other significant corporate events.
Investors researching CUE stock can review Form 10-K annual reports and Form 10-Q quarterly reports for detailed information on collaboration revenue, research and development spending, general and administrative expenses, cash and marketable securities, and risk factors related to the development of its Immuno-STAT® platform and pipeline candidates such as CUE-101, CUE-102, CUE-401 and CUE-501.
Form 8-K current reports are particularly relevant for Cue Biopharma, as they document material events including collaboration and license agreements, public offerings under its Form S-3 shelf registration statement, changes in executive leadership, facility lease amendments and key licensing transactions like the collaboration with ImmunoScape for the CUE-100 series. These filings often reference press releases furnished as exhibits, providing additional context on clinical and business developments.
This page also helps users locate information related to equity compensation and executive arrangements, which are described in employment agreements and separation agreements disclosed in 8-K filings. While Cue Biopharma’s insider transactions would appear in Form 4 filings submitted by individual officers and directors, aggregating these documents alongside periodic reports offers a fuller picture of governance and ownership activity.
Stock Titan enhances access to Cue Biopharma’s SEC filings with AI-powered summaries that explain key points from lengthy documents, highlight notable changes from prior periods and surface items that may be important to shareholders. Real-time updates from EDGAR ensure that new 10-K, 10-Q, 8-K and related forms are available promptly, helping users navigate the regulatory record behind CUE stock.
Cue Biopharma, Inc. held its 2026 annual meeting, where stockholders elected six directors and ratified the company’s independent auditor. A non-binding advisory proposal on executive compensation was also approved.
Stockholders further approved an amendment authorizing a reverse stock split of common stock at a ratio between 1-for-30 and 1-for-50, with the exact ratio and timing left to the Board’s sole discretion without further stockholder approval.
Cue Biopharma, Inc. reported that SVP and General Counsel Colin Sandercock received a grant of stock options on Common Stock. The award covers 200,000 stock options with an exercise price of $0.29 per share and an expiration date of April 8, 2036.
These options vest over four years, with 25% vesting on the one-year anniversary of the grant date and the remaining options vesting in equal semi-annual installments thereafter. Following this grant, Sandercock holds 200,000 stock options directly, reflecting a routine compensation-related equity award rather than an open-market transaction.
Cue Biopharma, Inc. reported that Chief Business Officer Lucinda Warren received a grant of stock options covering 250,000 shares of common stock. The options have an exercise price of $0.29 per share and expire on April 8, 2036.
The award vests over four years, with 25% vesting on the first anniversary of the grant date and the remaining options vesting in equal semi-annual installments thereafter. Following this grant, Warren holds 250,000 stock options directly.
Cue Biopharma, Inc. reported that Chief Development Officer Daniel G. Baker received a grant of stock options covering 100,000 shares of Common Stock. The options have an exercise price of $0.29 per share and expire on April 8, 2036.
The award vests over four years, with 25% of the options vesting on the first anniversary of the grant date and the remaining options vesting in equal semi-annual installments thereafter. Following this grant, Baker holds 100,000 stock options directly.
Cue Biopharma, Inc. reports that partner Boehringer Ingelheim has selected its first compound for lead optimization under their April 2025 collaboration focused on differentiated B cell depletion molecules, including Cue’s CUE-501 candidate. This preclinical milestone triggers a $7.5 million payment to Cue Biopharma, which is expected in May 2026.
The company notes that, despite this milestone, it continues to face risks typical for an early-stage biotech, including limited operating history, limited cash, a history of losses, and a current going concern determination about its ability to fund operations beyond the next twelve months.
Cue Biopharma announced a leadership change, appointing Chief Financial and Business Officer Lucinda Warren as Interim President and Chief Executive Officer effective March 27, 2026. She will also retain her finance and business responsibilities and receives a base salary of $525,000 plus a $10,000 monthly interim supplement.
Warren is eligible for an annual bonus up to 45% of base salary and a future stock option equal to about 1.0% of outstanding shares upon achieving a financing milestone. Former CEO Usman Azam resigned on March 26, 2026 and will receive cash severance of $232,500 and up to 12 months of COBRA premium payments under a separation agreement.
Cue Biopharma, Inc. has filed an S-3 registration statement to register up to $300,000,000 of securities, covering debt, common and preferred stock, subscription rights, units and warrants. The filing also includes an at-the-market sales agreement with Jefferies to sell up to $12,666,282 of common stock from time to time.
The prospectus states the ATM agent fee is 3.0% of gross proceeds and cites a public float of $37,998,848 based on March 13, 2026 and 97,283,278 shares held by non-affiliates. The prospectus emphasizes that specific terms for any offering will be set forth in prospectus supplements and warns of the risks described under "Risk Factors."
Cue Biopharma, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on April 13, 2026. The agenda includes electing seven directors for one-year terms, ratifying RSM US LLP as auditor, and an advisory vote on executive compensation.
A key proposal seeks approval to amend the certificate of incorporation to allow a reverse stock split of common shares at a ratio between 1-for-30 and 1-for-50, with exact timing and ratio left to the board’s discretion. The record date is March 9, 2026, when 97,660,791 common shares were outstanding.